Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.

Blood - 15 Mar 2008

Alici Evren, Sutlu Tolga, Björkstrand Bo, Gilljam Mari, Stellan Birgitta, Nahi Hareth, Quezada Hernan Concha, Gahrton Gösta, Ljunggren Hans-Gustaf, Dilber M Sirac

Abstract excerpt

Multiple myeloma (MM) is an incurable plasma cell malignancy with poor outcome. The most promising therapeutic options currently available are combinations of transplantation, targeted pharmacotherapy, and immunotherapy. Cell-based immunotherapy after hematopoietic stem-cell transplantation has been attempted, but with limited efficacy. Natural killer (NK) cells are interesting candidates for new means of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Separation

Share to Cell Survival

Share to Cytotoxicity, Immunologic

Share to Killer Cells, Natural

Share to Multiple Myeloma

Share to Receptors, Immunologic

Source

Identifiers

PMID: 18192509
DOI: 10.1182/blood-2007-09-110312

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.PMID 18192509Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.Semantic proximity Read ↗

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the futureSemantic proximity Read ↗

Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapseSemantic proximity Read ↗

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.Semantic proximity Read ↗

Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic StrategiesSemantic proximity Read ↗

Single-cell profiling of human bone marrow reveals multiple myeloma progression is accompanied by an increase in CD56 <sup>bright</sup> bone marrow resident NK cellsSemantic proximity Read ↗

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Semantic proximity Read ↗

Supercharged NK Cells Are a Unique Population of Cells Based on Transcriptomic, Single-Cell RNAseq, Proteomic, and Functional Characteristics; Comparison with Other NK Cell SubpopulationsSemantic proximity Read ↗

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK cells with Enhanced Antitumor Activity.Semantic proximity Read ↗

A Novel Feeder cell based on 4-1BBL and Membrane-bound IL-21/ IL-15 Induce Highly Expansion and Anti-tumor Effect of Natural Killer CellsSemantic proximity Read ↗

Adoptive NK cell therapy in AML: progress and challengesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.